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Abstract
Currently, about 50% of patients with metastatic renal cell carcinoma (mRCC) receive a second-line therapy. Therefore, the choice 
at each subsequent treatment line remains an important issue. In this retrospective study, we sought to identify pretreatment clinical 
parameters that could predict the likelihood of a patient receiving a second-line therapy. One hundred and sixty-one mRCC patients 
who received targeted therapy were evaluated. Descriptive statistics, Kaplan–Meier overall survival (OS), Cox regression, and binary 
logistic regression models were used for data analysis. Second-line therapy was given to 105 patients (65%). Patients with grade 1 
tumor received second-line therapy more frequently than those with grade 2/3 tumors (P = 0.03). Only tumor grade was significantly 
different between patients receiving, or not receiving, second-line treatment. Median OS was significantly superior in patients receiving 
second-line therapy (32 versus 14 months; P = 0.007; hazard ratio [HR], 1.75; P = 0.008), patients with grade 1 tumors (130 versus 
29 months in G2/3 tumors; HR, 3.85; P = 0.009), and in patients without early tumor progression (41 versus 11 months; HR, 5.04; 95% 
confidence interval [CI], 3.06–8.31; P < 0.001). In binary logistic regression, we identified early progression to be significantly associ-
ated with a higher probability of not receiving a second-line therapy (HR, 2.50; 95% CI, 1.01–6.21; P = 0.048). This study hypothesizes 
that pretreatment grade and early progression are predictive parameters for the selection of patients for second-line therapy.
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Targeted therapies have become the mainstay of treatment for 
metastatic renal cell carcinoma (mRCC), currently achieving 
a median overall survival (OS) of approximately 30 months 
(1). The recent improvements in targeted therapies enable 
clinicians to offer patients several lines of agents. However, 
in contrast to the expanded therapeutic armamentarium, only 
42%–57% of mRCC patients receive a second-line therapy 
(2, 3). During the cytokine era of mRCC therapy, the Memo-
rial Sloan Kettering Cancer Center (MSKCC) score proved to 
be a reliable predictor of patients receiving first-line immu-
notherapy with poor, intermediate, and good prognosis (4). 
Heng et al. (5) validated a modified prognostic scoring sys-
tem, based on the MSKCC, for the era of first-line targeted 
therapies. The International Metastatic Renal Cell Carci-
noma Database Consortium (IMDC), primarily designed for 
risk-assessment prior to initiating first-line therapy, recently 
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validated it for risk prediction in second-line therapy. The 
IMDC score is also based on the MSKCC score and includes 
the following variables to stratify mRCC patients into poor, 
intermediate, and good outcome: Karnofsky Performance 
Status, platelet count, neutrophil count, hemoglobin concen-
tration, serum calcium concentration, and time from diagno-
sis to treatment (6).
Apart from established risk stratification scores, there 
are various hematological, genetic, and anatomical param-
eters that have been analyzed for their predictive impact. 
For example, although metastatic tumor burden in three- 
dimensional volumetric analysis does not predict survival 
of mRCC patients, a composite biomarker score consisting 
of five biomarkers in the blood was significantly associated 
with progression-free survival (PFS) in mRCC patients 
treated with everolimus (7–9). The systemic inflammation 
response index based on widely available laboratory findings 
(hemoglobin concentration and lymphocyte-to- monocyte 
ratio) predicts OS and seems to be a better option (10). On 
the other hand, a genetically based approach would be to 
analyze polymorphisms of vascular endothelial growth fac-
tor A (VEGF A) receptor for their association with PFS (11).
Although these parameters might be useful in predict-
ing patient survival and treatment outcome, they cannot 
be used to make recommendations for specific therapeutic 
approaches. Moreover, there is no established model or sin-
gle parameter prior to first-line therapy that could predict 
whether, or not, a patient would require a second-line tar-
geted therapy. The aim of this study was to find pretreatment 
clinical parameters as a predictor of patients who will be 
capable to receive a second-line therapy. Such parameters 




Patients with mRCC, treated with targeted agents in our 
department (Department of Hematology, Hannover Medi-
cal School, Hannover, Germany), were identified retrospec-
tively from medical records. All patients receiving tyrosine 
kinase inhibitors (TKI) as first-line targeted agents from 2005 
to 2012 were eligible. There were no exclusion criteria. We 
defined first-line therapy as the first administered TKI within 
the treatment history for mRCC. Any other systemic therapy 
after first-line TKI treatment was defined as second-line ther-
apy. Discontinuation of first-line treatment was due to pro-
gressive disease, therapy-limiting toxicity, or patient request. 
Second-line treatment was administered after discontinuation 
of first-line therapy irrespective of the reason for discontin-
uation. Patients were treated with second-line therapy when 
eligible according to applicable treatment guidelines and 
local standards that included ECOG status, laboratory find-
ings, and patient approval. Early progression was defined as 
progressive disease within 6 months of start of first-line TKI 
therapy. Progression was defined by radiological evidence of 
disease progression, clinical signs of progression, or death 
from disease. Dose modifications were made according to 
the summary of medical product characteristics. Treatment 
and therapeutic monitoring, based on computed tomographic 
scans every 3 months, were applied according to guidelines 
and local standard. Clinical data were extracted from medi-
cal charts and collected in a database. Data were assessed by 
physicians and data managers. The database was last updated 
in April 2013. Patients’ data were assessed in an anonymized 
manner in concordance with recommendations of the local 
ethics committee and the declaration of Helsinki in its latest 
revised version.
Statistical analyses
All patients were divided into two subgroups for compari-
son: patients who received second-line therapy and patients 
who did not. The data were analyzed and compared by 
either Mann–Whitney test for parameters with more than 
two variables or Fisher’s exact test for categorical data. OS 
was calculated by Kaplan–Meier analysis, and subgroups 
were compared by log-rank test. Uni- and multivariate Cox 
regression models were conducted to analyze the associ-
ation between survival and administration of second-line 
therapy for different clinical and patient covariates. OS was 
defined from the time of first-line TKI treatment initiation 
until death, or last follow-up. Patients lost to follow-up 
were censored at time of last documented follow-up. Addi-
tionally, uni- and multivariate binary logistic regression 
analyses were performed to determine the usefulness of 
pretreatment clinical characteristics as predictors of abil-
ity to receive a second-line therapy. A hazard ratio (HR) 
describes the relative risk of not being able to obtain a 
second-line therapy. SPSS 21.0 was used for statistical 




Within the observation period, we identified 161 mRCC 
patients treated with first-line TKI. The median follow-up was 
33 (interquartile range, 11–40.5) months. At last follow-up, 
115 patients were alive while 46 patients had died. One hundred 
and nine patients (67.7%) were men. The predominant sub-
type was clear cell carcinoma (134 patients; 83.2%; Table 1). 
Sunitinib was the most frequently administered first-line agent 
(77%), followed by sorafenib (14.9%), axitinib (5.0%), and 
pazopanib (3.1%). The performance status defined by ECOG 
was 0 in the majority of patients (68.3%) and 1 in 8.7% of 
patients. Prior immunotherapy was documented in 38.5% of 
patients. Although 55.9% of patients had no available record 
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Table 1. Baseline parameters of all patients, and comparison of patients receiving second-line therapy with patients not receiving 
second-line therapy
All Second line No second line P-value
Patients 161 105 56
Gender, n (%)
 Male 109 (67.7) 74 (70.5) 35 (62.5) 0.376
 Female 52 (32.3) 31 (29.5) 21 (37.5)
Histology, n (%)
 Clear cell 134 (83.2) 85 (81.0) 49 (83.2) 0.304
 Papillary 7 (4.3) 6 (5.7) 1 (1.8)
 Others 7 (4.4) 6 (5.7) 1 (1.8)
 NE 13 (8.1) 8 (7.6) 5 (8.9)
Grading, n (%)
 G1 9 (5.6) 9 (8.6) 0 (0) 0.030
 G2/3 131 (81.3) 85 (80.9) 46 (83.1)
 NE 21 (13.0) 11 (10.5) 10 (17.9)
T (2002), n (%)
 1 26 (16.1) 16 (15.2) 10 (17.9) 0.216
 2 26 (16.1) 22 (21.0) 4 (7.1)
 3 68 (42.2) 42 (40.0) 26 (46.4)
 4 6 (3.7) 4 (3.8) 2 (3.6)
 NE 35 (21.7) 21 (20.0) 14 (25.0)
N, n (%)
 Negative 75 (46.6) 54 (52.4) 21 (37.5) 1.0
 Positive 18 (11.2) 13 (12.4) 5 (9.9)
 NE 68 (42.2) 38 (36.2) 30 (53.6)
M, n (%)
 0 51 (31.7) 34 (32.4) 17 (30.4) 0.375
 1 45 (28.0) 34 (32.4) 11 (19.6)
 NE 65 (40.4) 37 (35.2%) 28 (17.4)
ECOG, n (%)
 0 110 (68.3) 75 (71.4) 35 (62.5%) 0.547
 ≥1 14 (8.7) 8 (7.7) 6 (10.7)
 NE 37 (23.0) 22 (13.7) 15 (26.8)
(Continued)
Predictive Factors for Second-Line Therapy
Journal of Kidney Cancer and VHL 2017;4(1):8–15 11
of an MSKCC risk score, most patients at onset of mRCC 
presented an intermediate risk score (n = 50; 31.1%; Table 1).
Characteristics for second-line patients
One hundred and five patients (65%) received a second-line 
therapy, whereas 56 patients (35%) did not. Comparison of 
clinical and histopathological pretreatment baseline param-
eters between patients who did and did not receive sec-
ond-line therapies failed to demonstrate a statistically signif-
icant difference (Table 1). However, analysis of histological 
grading showed that more patients with pretreatment grade 
1 tumor received a second-line therapy than those with grade 
2/3 tumors (P = 0.03; Table 1). Furthermore, patients with-
out early progression tended to receive a second-line therapy 
more frequently than those who had an early progression (P 
= 0.063; Table 1).
Second-line therapy is associated with a better OS
The median OS for all patients was 30 months (95% con-
fidence interval [CI], 25.3–34.7). Kaplan–Meier analysis 
disclosed a median OS of 32 months (95% CI, 27.0–37.0) 
for patients receiving second-line therapy compared to 
patients who did not (median OS, 14 months; 95% CI, 8.4–
19.6 months; log-rank: P = 0.007; Figure 1). In  univariate 
analysis, application of second-line therapy was associated 
with better OS (HR, 1.75; 95% CI, 1.16–2.65; P = 0.008; 
Table 2). Additionally, the pretreatment grade 1 tumor was 
associated with improved median OS compared to pretreat-
ment grade 2/3 tumors (130 months [95% CI, 25.7–234.3] 
versus 29 months [95% CI, 24.2–33.8]; log-rank P = 0.009; 
HR, 3.85; Table 2). Other factors such as ECOG perfor-
mance status, MSKCC risk score, the presence of synchro-
nous metastases, prior cytokine use, and early progression 
were also shown to be prognostic factors (Table 2). No 
independent risk parameter could be identified in multivar-
iate analysis.
Prognostic value of patient characteristics on 
 second-line treatment administration
We tested all clinical parameters displayed in Table 1 accord-
ing to the impact of second-line treatment administration by 
binary logistic regression. Early progression, defined as pro-
gression within 6 months of the start of first-line therapy, was 
MSKCC, n (%)
 Favorable 16 (9.9) 8 (7.6) 8 (14.3) 0.584
 Intermediate 50 (31.1) 30 (28.6) 20 (35.7)
 Unfavorable 5 (3.1) 2 (1.9) 3 (5.4)
 NE 90 (55.9) 65 (61.9) 25 (44.6)
Metastatic sites, n (%)
 1 57 (35.4) 44 (41.9) 13 (23.2) 0.225
 >1 62 (38.5) 41 (39.0) 21 (37.5)
 NE 42 (26.1) 20 (19.0) 22 (39.3)
Cytokine, n (%)
 Yes 62 (38.5) 44 (41.9) 18 (32.1) 0.236
 No 98 (60.9) 60 (57.1) 38 (67.9)
 NE 1 (0.6) 1 (1.0) 0 (0)
PD ≤ 6 months, n (%)
 Yes 38 (23.6) 23 (21.9) 15 (26.8) 0.063
 No 58 (36.0) 46 (43.8) 12 (21.4)
 NE 65 (40.4) 36 (34.3) 29 (51.8)
NE: not evaluable, PD ≤ 6 months: progressive disease within 6 months of first-line therapy.
Table 1. (Continued )
All Second line No second line P-value
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significantly associated with an increased risk of not being able 
to receive a second-line therapy (HR, 2.50; 95% CI, 1.01–6.21; 
P = 0.048). However, none of the parameters were identified as 
independent risk parameter in the multivariate analysis.
Discussion
The aim of this study was to identify prognostic base-
line parameters that might help to identify whether mRCC 
patients would receive a second-line therapy. Currently, in 
Europe, mRCC patients have access to an armamentarium 
of 11 active agents; however, there is an increasing body of 
evidence that only a minority of patients enter a second-line 
therapy (12). The reasons for the high dropout rate before 
patients enter second-line therapy are largely unknown. How-
ever, death related to rapid tumor progression during first-line 
therapy does not explain this phenomenon sufficiently (12). 
Knowledge about baseline parameters of patients who will be 
able to enter a second-line therapy is an important issue, in 
particular, because immunotherapeutic agents could soon be 
introduced in the first-line setting. This will confront treating 
physicians in the near future with an increased challenge to 
choose the right agent for the right patient.
Our results show a significant difference in baseline char-
acteristics between patients who received second-line therapy 
and patients who did not. Grade 1 tumors were significantly 
more frequent in patients who received second-line therapy. In 
fact, grade 1 tumors were found only in patients who received 
the second-line therapy (8.6% versus 0.0%; P = 0.03). Cor-
respondingly, the OS of mRCC patients with G1 tumors was 
significantly longer than those with G2/3 tumors (median OS 
in months, 130 [95% CI, 25.7–234.3] versus 29 [95% CI, 
24.2–33.8]; log-rank P = 0.009; HR, 3.85). Nonetheless, this 
parameter was not identified as an independent risk predictor 
for second-line receiver. Therefore, we hypothesize that higher 
grading might be associated with a likelihood for a patient not 
receiving a second-line therapy and vice versa. Additionally, 
early progression was an impediment for patients to receive a 
second-line therapy. In univariate analysis, early progression 
was the only parameter significantly associated with dimin-
ished OS and a higher risk of not being able to receive a sec-
ond-line therapy (HR, 2.50; 95% CI, 1.01–6.21; P = 0.048). 
However, this parameter was not identified as an independent 
risk predictor for second-line receiver. The retrospective nature 
of a single-center analysis is naturally limited and most likely 
carries a selection bias. Limited sample number, missing data, 
and retrospective data acquisition represent the major limita-
tions of this study, potentially over- or underpowering the cur-
rent identified trends. However, we suggest that our analysis 
does at least have a character of hypothesis generation.
Previous studies have shown that grading is a valuable 
prognostic tool in mRCC and predicts OS (12–14). The study 
of Sacré et al. (15) identified grading to be a prognostic factor 
at the start of second-line therapy. To our knowledge, there is 
no study so far that has identified pretreatment tumor grade 
as the predictor of eligibility to receive second-line therapy. 
Although preliminary with limited samples from a single 
center, these findings warrant further exploration to eluci-
date the prognostic significance of grading toward clinical 
decision making. Patients with an aggressive tumor biology 
Figure 1. Kaplan–Meier analysis displaying improved median OS for patients receiving second-line therapy (32 versus 14 months; P = 
0.007).
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might benefit from a specific therapeutic approach that has 
yet to be defined.
Furthermore, early progression could be identified as a 
parameter of prognostic value in the prediction of patients 
who will be able to receive second-line therapy. This notion 
is supported by previous findings. For example, the depth of 
remission during first-line therapy proved to be an independ-
ent prognostic factor. Early tumor shrinkage and the depth 
of remission were significantly associated with an improved 
OS (16). However, early progression itself is technically not 
Table 2. Univariate analysis of patient characteristics related to OS
OS, months,  
median (95% CI)
HR (95% CI) P-value
M
 0 (indicator) 40 (28.4–51.6) 1.69 (1.04–2.73) 0.034
 1 25 (17.6–32.4)
ECOG
 0 (indicator) 30 (24.2–35.8) 3.82 (2.05–7.13) <0.001
 ≥1 9 (6.3–11.8)
MSKCC
 Favorable 37 (28.4–45.6)
 Intermediate 16 (9.7–22.3) 1.84 (0.89–3.82)
0.102 (favorable versus 
intermediate)
 Unfavorable 4 (1.9–6.1) 2.26 (1.23–4.15)
0.009 (favorable versus un 
favorable)
 Unknown 32 (23.7–40.3) 0.97 (0.77–1.23)
0.817 (favorable versus 
unknown)
PD ≤ 6 months
 No (indicator) 41 (24.4–57.6) 5.04 (3.06–8.31) <0.001
 Yes 11 (6.4–15.6)
Metastatic sites
 1 (indicator) 30 (22.4–37.6) 1.48 (0.98–2.24) 0.062
 >1 30 (22.0–38.0)
Cytokine
 Yes (indicator) 49 (35.5–62.5) 2.73 (1.78–4.18) <0.001
 No 20 (14.5–25.5)
TKI second line
 Yes (indicator) 32 (27.0–37.0) 1.75 (1.16–2.65) 0.008
 No 14 (8.4–19.6)
Grading
 G1 130 (25.7–234.3) 3.85 (1.40–10.63) 0.009
 G2/3 29 (24.2–33.8)
PD ≤ 6 months: progressive disease within 6 months of first-line therapy.
Eggers et al.
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a baseline parameter, which will generate problems because 
clinicians cannot base therapeutic decision making on this 
parameter up front of first-line therapy. Other prognostic 
markers and clinical scoring systems reliably predict OS 
ahead of first-line therapy. The original MSKCC score, the 
International Kidney Cancer Working Group, and the IMDC 
score are tools that are utilized in the clinic (17). By reli-
ably predicting OS, these scores might guide us in thera-
peutic decision making. However, these parameters are not 
validated to predict the likelihood to receive a second-line 
therapy.
Keeping these in mind, reviews about sequential therapies 
and decision making have been extensively published (18–
20). There are international and national guidelines, as well 
as reliable phase 3 studies on therapy of RCC. Moreover, var-
ious studies focused on predictive and prognostic markers of 
RCC. For example, a retrospective study of Al-Marrawi et al. 
(21) showed that response to second-line VEGF therapy does 
not depend on response to first-line therapy. Another study 
concluded that an early reduction in neutrophil-to-lympho-
cyte ratio indicates a survival benefit (21). Various studies 
also attempted to predict response to VEGF-targeted thera-
pies by focusing on circulating proteins, tissue-based mol-
ecules, germ line polymorphisms, and genomic biomarkers. 
However, no definitive biomarker has yet been integrated into 
the clinical decision making in therapy naive mRCC patients 
(22, 23). These studies may give advice on clinical decision 
making but cannot predict the likelihood of a patient requir-
ing second-line therapy. In contrast, our retrospective study is 
the first that identified pretreatment parameters predicting the 
eligibility to receive a second-line therapy.
In conclusion, our results support the hypothesis that 
patients with a high-grade tumor inherit poor prognosis, 
which might be associated with a likelihood not to receive 
a second-line therapy. Importantly, this study identifies early 
progression to be a parameter of prognostic value identifying 
patients who will not receive a second-line therapy. However, 
further research is necessary to elucidate the role of grading 
and early progression in RCC to identify patients with a high 
likelihood of receiving a second-line therapy.
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